News
ADAG
3.400
+2.72%
0.090
Analysts’ Top Healthcare Picks: Adagene (ADAG), AbbVie (ABBV)
TipRanks · 1d ago
Adagene’s Platform Partnerships and Muzastotug Catalysts Support Buy Rating, Price Target Unchanged at $8
TipRanks · 2d ago
Adagene Deepens Third Arc Bio Partnership as First SAFEbody-Based CD3 Lead Selected
TipRanks · 2d ago
Third Arc Bio Selects First Lead Candidate Upon 2025 Amended Strategic License Deal With Adagene
Benzinga · 2d ago
Adagene Price Target Announced at $9.00/Share by Chardan Capital
Dow Jones · 2d ago
Adagene Initiated at Buy by Chardan Capital
Dow Jones · 2d ago
Chardan Capital Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
Benzinga · 2d ago
Adagene initiated with a Buy at Chardan
TipRanks · 2d ago
Adagene Secures Milestone Payments in Exelixis SAFEbody ADC Collaboration
TipRanks · 3d ago
Adagene announces $2M milestone payment from Exelixis
TipRanks · 3d ago
Weekly Report: what happened at ADAG last week (0831-0904)?
Weekly Report · 5d ago
Weekly Report: what happened at ADAG last week (0824-0828)?
Weekly Report · 08/31 10:10
Weekly Report: what happened at ADAG last week (0817-0821)?
Weekly Report · 08/24 10:11
Analysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Natera (NTRA)
TipRanks · 08/17 15:20
Weekly Report: what happened at ADAG last week (0810-0814)?
Weekly Report · 08/17 10:12
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)
TipRanks · 08/13 11:10
Adagene Extends Cash Runway and Advances Muzastotug Through Mid-2026 Clinical Milestones
TipRanks · 08/12 11:57
Adagene ADR Non-GAAP EPS of -$0.20, revenue of $1.62M
Seeking Alpha · 08/12 11:51
Adagene H1 Adj. EPS $(0.20) Misses $(0.10) Estimate, Sales $1.620M
Benzinga · 08/12 11:33
Weekly Report: what happened at ADAG last week (0803-0807)?
Weekly Report · 08/10 10:07
More
Webull provides a variety of real-time ADAG stock news. You can receive the latest news about Adagene Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ADAG
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.